)
Nurix Therapeutics (NRIX) investor relations material
Nurix Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Advanced lead BTK degrader, bexobrutideg, into pivotal Phase 2 and planned Phase 3 trials for CLL, showing strong efficacy and safety in clinical data presented at ASH 2025.
Expanded pipeline in oncology and immunology, including progress in partnered programs with Sanofi and Gilead, and strengthened financial position with $592.9M in cash and a $250M equity offering.
Strategic priorities for 2026 include advancing bexobrutideg in CLL and I&I, supporting partnered programs, and expanding the pipeline.
Voting matters and shareholder proposals
Election of three Class III directors for three-year terms.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
Advisory vote on executive compensation (say-on-pay).
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board is divided into three staggered classes; separation of CEO and Chair roles.
Majority of directors are independent; annual self-evaluations conducted with third-party facilitation.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Clinical and Commercialization.
Board and committees met regularly in 2025, with high attendance.
- Director elections, auditor ratification, and say-on-pay up for vote at 2026 annual meeting.NRIX
Proxy filing27 Mar 2026 - Degrader therapies in immunology advance with key programs and major milestones expected this year.NRIX
Piper Sandler Virtual Novel Targets in Immunology Symposium12 Feb 2026 - Bexabrutadeg achieves high response rates in resistant cancers, driving pivotal trials and pipeline growth.NRIX
H.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026 - Bexdeg CLL data, pivotal study plans, and partnered STAT6/IRAK4 programs drive pipeline momentum.NRIX
Jefferies Global Healthcare Conference 20253 Feb 2026 - NX-5948 heads to pivotal trials as pipeline and partnerships drive major 2024 catalysts.NRIX
Oppenheimer 35th Annual Healthcare Life Sciences Conference 20253 Feb 2026 - NX-5948 achieved a 70% response rate in CLL, with pivotal trials set for 2025.NRIX
UBS Targeted Protein Degradation Day 20243 Feb 2026 - NX-5948 delivered rapid, durable responses in high-risk CLL, supporting pivotal trials in 2025.NRIX
Study Update3 Feb 2026 - BTK degraders show high efficacy in resistant CLL, with strong financial backing for pipeline growth.NRIX
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Advanced pivotal CLL trials, grew revenue, and maintained strong cash reserves.NRIX
Q4 202528 Jan 2026
Next Nurix Therapeutics earnings date
Next Nurix Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)